The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Clinical Relevance of C-Reactive Protein During Follow-Up of Patients With Acute Coronary Syndromes in the Aggrastat-to-Zocor Trial
Open accessAbstract
Background— Elevated levels of high-sensitivity C-reactive protein (hsCRP) are associated with higher risk of adverse outcomes in patients at risk for or with established coronary artery disease. Retrospective analyses suggest that this risk may be modified with statin therapy. However, a role for hsCRP in monitoring the success of therapy remains uncertain. Methods and Results— We measured the serum concentration of hsCRP at 30 days (n=3813) and 4 months in patients with non–ST-elevation or ST-elevation acute coronary syndrome randomly assigned to an early intensive versus delayed conservative simvastatin strategy in the Aggrastat-to-Zocor Trial. Patients with hsCRP >3 mg/L at 30 days had significantly higher 2-year mortality rates than those with hsCRP 1 to 3 mg/L or hsCRP <1 mg/L (6.1% versus 3.7% versus 1.6%, P <0.0001). Results were similar with hsCRP measured at 4 months. After adjusting for age, gender, diabetes, smoking, cardiovascular history, index event, lipid levels, and randomly assigned treatment, patients with hsCRP >3 mg/L were at more than 3-fold higher risk of death (HR, 3.7; 95% CI, 1.9 to 7.2) compared with those with hsCRP <1 mg/L. “Average” levels of hsCRP (1 to 3 mg/L) were also associated with increased risk compared with those with hsCRP <1 mg/L (HR, 2.3; 95% CI, 1.2 to 4.6). Patients allocated to early intensive statin therapy were more likely to achieve hsCRP levels <1 mg/L at 30 days ( P =0.028) and 4 months ( P <0.0001). Conclusions— Achieved levels of hsCRP at 30 days and 4 months after acute coronary syndrome are independently associated with long-term survival. Patients treated with more aggressive statin therapy are more likely to achieve lower levels of hsCRP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Inflammation and Atherosclerosis
Libby, P., Ridker, P. M., & Maseri, A. (2002) · Circulation · doi:10.1161/hc0902.104353 · Cited by 7,724
Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., Criqui, M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L., et al. (2003) · Circulation · doi:10.1161/01.cir.0000052939.59093.45 · Cited by 6,401
Self-citationC-Reactive Protein Levels and Outcomes after Statin Therapy
Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042378 · Cited by 2,292
Self-citationDirect Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells
Pasceri, V., Willerson, J. T., & Yeh, E. T. H. (2000) · Circulation · doi:10.1161/01.cir.102.18.2165 · Cited by 1,940
Ridker, P. M., Rifai, N., Clearfield, M., Downs, J. R., Weis, S. E., Miles, J. S., & Gotto, A. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106283442601 · Cited by 1,557
Self-citationRidker, P. M., Rifai, N., Pfeffer, M. A., Sacks, F. M., Moye, L. A., Goldman, S., Flaker, G. C., & Braunwald, E. (1998) · Circulation · doi:10.1161/01.cir.98.9.839 · Cited by 1,389
Self-citationde Lemos, J. A., Blazing, M. A., Wiviott, S. D., Lewis, E. F., Fox, K. A. A., White, H. D., Rouleau, J.-L., Pedersen, T. R., Gardner, L. H., Mukherjee, R., et al. (2004) · JAMA · doi:10.1001/jama.292.11.1307 · Cited by 1,333
Self-citationStatin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease
Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Crowe, T., Sasiela, W. J., Tsai, J., Orazem, J., Magorien, R. D., O'Shaughnessy, C., & Ganz, P. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042000 · Cited by 1,325
Jialal, I., Stein, D., Balis, D., Grundy, S. M., Adams-Huet, B., & Devaraj, S. (2001) · Circulation · doi:10.1161/01.cir.103.15.1933 · Cited by 730
Cited by
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Inflammation in Atherosclerosis
Libby, P., Ridker, P. M., & Hansson, G. K. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.09.009 · Cited by 2,228
Jellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., Grunberger, G., Guerin, C. K., Bell, D. S. H., Mechanick, J. I., et al. (2017) · Endocrine Practice · doi:10.4158/ep171764.appgl · Cited by 1,094
Ridker, P. M. (2016) · Circulation Research · doi:10.1161/circresaha.115.306656 · Cited by 1,002
Ridker, P. M., Danielson, E., Fonseca, F. A., Genest, J., Gotto, A. M., Kastelein, J. J., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60447-5 · Cited by 1,010
NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis
Grebe, A., Hoss, F., & Latz, E. (2018) · Circulation Research · doi:10.1161/circresaha.118.311362 · Cited by 926
Ridker, P. M., MacFadyen, J. G., Everett, B. M., Libby, P., Thuren, T., Glynn, R. J., Ridker, P. M., MacFadyen, J. G., Everett, B. M., Libby, P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32814-3 · Cited by 919
Ridker, P. M., Thuren, T., Zalewski, A., & Libby, P. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.06.012 · Cited by 799
Inflammation in Atherosclerosis: Transition From Theory to Practice
Libby, P., Okamoto, Y., Rocha, V. Z., & Folco, E. (2010) · Circulation Journal · doi:10.1253/circj.cj-09-0706 · Cited by 799
Atherosclerosis and inflammation: overview and updates
Geovanini, G. R., & Libby, P. (2018) · Clinical Science · doi:10.1042/cs20180306 · Cited by 703
Varbo, A., Benn, M., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2013) · Circulation · doi:10.1161/circulationaha.113.003008 · Cited by 692
Ridker, P. M., Bhatt, D. L., Pradhan, A. D., Glynn, R. J., MacFadyen, J. G., & Nissen, S. E. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00215-5 · Cited by 672
C-Reactive Protein and the Prediction of Cardiovascular Events Among Those at Intermediate Risk
Ridker, P. M. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.052 · Cited by 623
Jellinger, P. S., Smith, D. A., Mehta, A. E., Ganda, O., Handelsman, Y., Rodbard, H. W., Shepherd, M. D., & Seibel, J. A. (2012) · Endocrine Practice · doi:10.4158/ep.18.s1.1 · Cited by 533
Ridker, P. M., Howard, C. P., Walter, V., Everett, B., Libby, P., Hensen, J., & Thuren, T. (2012) · Circulation · doi:10.1161/circulationaha.112.122556 · Cited by 530
High-Sensitivity C-Reactive Protein and Cardiovascular Disease
Yousuf, O., Mohanty, B. D., Martin, S. S., Joshi, P. H., Blaha, M. J., Nasir, K., Blumenthal, R. S., & Budoff, M. J. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.016 · Cited by 494
Obesity and Inflammation: Epidemiology, Risk Factors, and Markers of Inflammation
Rodríguez-Hernández, H., Simental-Mendía, L. E., Rodríguez-Ramírez, G., & Reyes-Romero, M. A. (2013) · International Journal of Endocrinology · doi:10.1155/2013/678159 · Cited by 481
Inflammation and cardiovascular disease: From mechanisms to therapeutics
Alfaddagh, A., Martin, S. S., Leucker, T. M., Michos, E. D., Blaha, M. J., Lowenstein, C. J., Jones, S. R., & Toth, P. P. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100130 · Cited by 473
Targeting cardiovascular inflammation: next steps in clinical translation
Lawler, P. R., Bhatt, D. L., Godoy, L. C., Lüscher, T. F., Bonow, R. O., Verma, S., & Ridker, P. M. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa099 · Cited by 443
Ridker, P. M. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.11.037 · Cited by 414
Sabatine, M. S., Morrow, D. A., Jablonski, K. A., Rice, M. M., Warnica, J. W., Domanski, M. J., Hsia, J., Gersh, B. J., Rifai, N., Ridker, P. M., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.649939 · Cited by 385
Self-citationEverett, B. M., Pradhan, A. D., Solomon, D. H., Paynter, N., MacFadyen, J., Zaharris, E., Gupta, M., Clearfield, M., Libby, P., Hasan, A. A. K., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.03.018 · Cited by 368
“Achieved levels of hsCRP and LDL-C independently relate to the risk of recurrent events in a number of randomized trials of patients post acute coronary syndrome, including the PROVE IT-TIMI 22 and A to Z studies of usual versus intensive statin therapy.(13,14) When viewed together with JUPITER, data from these 3 tria…”
MethodKoenig, W. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.07.113 · Cited by 315
Inflammation in Atherosclerosis—No Longer a Theory
Libby, P. (2021) · Clinical Chemistry · doi:10.1093/clinchem/hvaa275 · Cited by 314
Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin
Ridker, P. M. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw024 · Cited by 304
Wong, N. D., Budoff, M. J., Ferdinand, K., Graham, I. M., Michos, E. D., Reddy, T., Shapiro, M. D., & Toth, P. P. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100335 · Cited by 302
Inflammatory and Cholesterol Risk in the FOURIER Trial
Bohula, E. A., Giugliano, R. P., Leiter, L. A., Verma, S., Park, J.-G., Sever, P. S., Lira Pineda, A., Honarpour, N., Wang, H., Murphy, S. A., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034032 · Cited by 280
Self-citationInflammation, C‐Reactive Protein, and Atherothrombosis
Ridker, P. M., & Silvertown, J. D. (2008) · Journal of Periodontology · doi:10.1902/jop.2008.080249 · Cited by 279
RIDKER, P. M. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03404.x · Cited by 270
Davidson, M. H., Ballantyne, C. M., Jacobson, T. A., Bittner, V. A., Braun, L. T., Brown, A. S., Brown, W. V., Cromwell, W. C., Goldberg, R. B., McKenney, J. M., et al. (2011) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.07.005 · Cited by 262
“These results were corroborated by the Aggrastat-to-Zocor (A to Z) trial, which compared early intensive statin treatment (simvastatin 40 mg/d for 30 days followed by 80 mg/d) to a delayed conservative statin strategy (placebo for 4 months followed by 20 mg/d simvastatin).(64) In the Reversal of Atherosclerosis with A…”
BackgroundKones, R. (2011) · Drug Design, Development and Therapy · doi:10.2147/dddt.s14934 · Cited by 259
Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy
Pradhan, A. D., Aday, A. W., Rose, L. M., & Ridker, P. M. (2018) · Circulation · doi:10.1161/circulationaha.118.034645 · Cited by 258
Ridker, P. M. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.119214 · Cited by 206
The Biological Role of Inflammation in Atherosclerosis
Wong, B. W., Meredith, A., Lin, D., & McManus, B. M. (2012) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.06.023 · Cited by 168
Kandelouei, T., Abbasifard, M., Imani, D., Aslani, S., Razi, B., Fasihi, M., Shafiekhani, S., Mohammadi, K., Jamialahmadi, T., Reiner, Ž., et al. (2022) · Mediators of Inflammation · doi:10.1155/2022/8732360 · Cited by 136
C-Reactive Protein: Clinical and Epidemiological Perspectives
Salazar, J., Martínez, M. S., Chávez, M., Toledo, A., Añez, R., Torres, Y., Apruzzese, V., Silva, C., Rojas, J., & Bermúdez, V. (2014) · Cardiology Research and Practice · doi:10.1155/2014/605810 · Cited by 117
Exercise intervention and inflammatory markers in coronary artery disease: A meta-analysis
Swardfager, W., Herrmann, N., Cornish, S., Mazereeuw, G., Marzolini, S., Sham, L., & Lanctôt, K. L. (2012) · American Heart Journal · doi:10.1016/j.ahj.2011.12.017 · Cited by 91
Targeting Inflammation to Reduce Residual Cardiovascular Risk
Ajala, O. N., & Everett, B. M. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00883-3 · Cited by 65
Metadata
- Authors
- Morrow, D. A., de Lemos, J. A., Sabatine, M. S., Wiviott, S. D., Blazing, M. A., Shui, A., Rifai, N., Califf, R. M., & Braunwald, E.
- Venue
- Circulation
- Published
- 2006-07-25
- Volume
- 114
- Issue
- 4
- Pages
- 281-288
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2119475547
- Cited by
- 313
- References
- 26
- FWCI
- 25.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.